HomeCompareEKTAY vs KMB

EKTAY vs KMB: Dividend Comparison 2026

EKTAY yields 2.25% · KMB yields 5.25%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 EKTAY wins by $635.00 in total portfolio value· pulled ahead in Year 10
10 years
EKTAY
EKTAY
● Live price
2.25%
Share price
$5.74
Annual div
$0.13
5Y div CAGR
33.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$46.6K
Annual income
$7,846.63
Full EKTAY calculator →
KMB
KMB
● Live price
5.25%
Share price
$96.35
Annual div
$5.06
5Y div CAGR
17%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$45.9K
Annual income
$5,222.34
Full KMB calculator →

Portfolio growth — EKTAY vs KMB

📍 EKTAY pulled ahead of the other in Year 10

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodEKTAYKMB
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, EKTAY + KMB cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
EKTAY pays
KMB pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

EKTAY
Annual income on $10K today (after 15% tax)
$191.36/yr
After 10yr DRIP, annual income (after tax)
$6,669.64/yr
KMB
Annual income on $10K today (after 15% tax)
$446.39/yr
After 10yr DRIP, annual income (after tax)
$4,438.99/yr
At 15% tax rate, EKTAY beats the other by $2,230.65/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of EKTAY + KMB for your $10,000?

EKTAY: 50%KMB: 50%
100% KMB50/50100% EKTAY
Portfolio after 10yr
$46.2K
Annual income
$6,534.48/yr
Blended yield
14.13%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on KMB right now

EKTAY
Analyst Ratings
1
Hold
Consensus: Hold
Altman Z
1.3
Piotroski
4/9
KMB
Analyst Ratings
9
Buy
19
Hold
3
Sell
Consensus: Hold
Price Target
$123.00
+27.7% upside vs current
Range: $102.00 — $162.00
Altman Z
3.4
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

EKTAY buys
0
KMB buys
0
No recent congressional trades found for EKTAY or KMB in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricEKTAYKMB
Forward yield2.25%5.25%
Annual dividend / share$0.13$5.06
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR33.3%17%
Portfolio after 10y$46.6K$45.9K
Annual income after 10y$7,846.63$5,222.34
Total dividends collected$23.3K$21.6K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples
Analyst consensusHoldHold

Year-by-year: EKTAY vs KMB ($10,000, DRIP)

YearEKTAY PortfolioEKTAY Income/yrKMB PortfolioKMB Income/yrGap
1$11,000$300.10$11,314$614.45$314.00KMB
2$12,181$411.25$12,867$760.19$686.00KMB
3$13,601$567.35$14,713$945.27$1.1KKMB
4$15,343$789.20$16,924$1,181.90$1.6KKMB
5$17,526$1,109.05$19,596$1,486.64$2.1KKMB
6$20,331$1,578.24$22,850$1,882.16$2.5KKMB
7$24,035$2,280.85$26,849$2,399.80$2.8KKMB
8$29,076$3,359.15$31,812$3,083.36$2.7KKMB
9$36,174$5,062.63$38,033$3,994.72$1.9KKMB
10← crossover$46,553$7,846.63$45,918$5,222.34+$635.00EKTAY

EKTAY vs KMB: Complete Analysis 2026

EKTAYStock

Elekta AB (publ), a medical technology company, provides clinical solutions for treating cancer and brain disorders worldwide. The company offers Versa HD, a brain metastases solution; Elekta Unity, a MR-Linac technology; Elekta Harmony, a linear accelerator; Elekta Infinity for treating a range of patients with simple-to-complex radiotherapy needs; Elekta Synergy, a digital accelerator for advanced image-guided radiation therapy; treatment management solutions; automated and integrated quality assurance solutions; and hardware and software motion management technology. It also provides MOSAIQ Plaza for multidisciplinary cancer care; Elekta Axis Cloud, a managed hosting service; Elekta Studio, an image-guided brachytherapy solution; ImagingRing, a mobile CT scanner; Oncentra Brachy, a smart tool that facilitate repetitive tasks; Venezia applicator that enables the radiation oncologist to treat locally advanced cervical cancer; Elekta Flexitron afterloader for enabling the precise execution of all steps in the workflow; and Geneva, an applicator for cervical cancer treatment. In addition, the company offers Leksell Gamma Knife Icon for personalized radiation treatment; Leksell Gamma Knife Perfexion, a tool for neurosurgeons; Leksell Gamma Knife Lightning for accelerated radiosurgery. Further, it provides neurosurgery products comprising Leksell Vantage Stereotactic System for intracranial neurosurgery; and Leksell Stereotactic System or minimally invasive stereotactic neurosurgery. The company was incorporated in 1972 and is headquartered in Stockholm, Sweden.

Full EKTAY Calculator →

KMBConsumer Staples

Kimberly-Clark Corporation, together with its subsidiaries, manufactures and markets personal care and consumer tissue products worldwide. It operates through three segments: Personal Care, Consumer Tissue, and K-C Professional. The Personal Care segment offers disposable diapers, swimpants, training and youth pants, baby wipes, feminine and incontinence care products, and other related products under the Huggies, Pull-Ups, Little Swimmers, GoodNites, DryNites, Sweety, Kotex, U by Kotex, Intimus, Depend, Plenitud, Softex, Poise, and other brand names. The Consumer Tissue segment provides facial and bathroom tissues, paper towels, napkins, and related products under the Kleenex, Scott, Cottonelle, Viva, Andrex, Scottex, Neve, and other brand names. The K-C Professional segment offers wipers, tissues, towels, apparel, soaps, and sanitizers under the Kleenex, Scott, WypAll, Kimtech, and KleenGuard brands. The company sells household use products directly to supermarkets, mass merchandisers, drugstores, warehouse clubs, variety and department stores, and other retail outlets, as well as through other distributors and e-commerce; and away-from-home use products directly to manufacturing, lodging, office building, food service, and public facilities, as well as through distributors and e-commerce. Kimberly-Clark Corporation was founded in 1872 and is headquartered in Dallas, Texas.

Full KMB Calculator →
📬

Get this EKTAY vs KMB comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

EKTAY vs SCHDEKTAY vs JEPIEKTAY vs OEKTAY vs KOEKTAY vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.